FDA Approves Rozanolixizumab-noli for Generalized Myasthenia Gravis
The treatment is the first approved by the FDA to treat the 2 most common subtypes of generalized myasthenia gravis.
Stay updated with breaking news from Gravis Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The treatment is the first approved by the FDA to treat the 2 most common subtypes of generalized myasthenia gravis.
/PRNewswire/ -- The MG Community around the world is turning Awareness into Action in June to educate everyone about the challenges of the rare neuromuscular...
/PRNewswire/ -- Two patient-centric advocacy organizations have created an alliance to help patients with chronic disease navigate the health care system....
/PRNewswire/ -- The Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization solely dedicated to the myasthenia...
Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with generalized...